title: [Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy].
abstract: BACKGROUND
  In patients with moderate to severe cancer pain receiving treatment with opioid analgesics, the treatment was switched from the existing opioid analgesic to the 1-day fentanyl patch (the "1-day formulation"), and the efficacy and safety of the 1-day formulation were evaluated.
  
  
  METHODS
  The preceding opioid analgesic therapy was switched to therapy with the 1-day formulation, at a dose level corresponding to the daily dose level of the preceding opioid analgesic. The pain control rate was evaluated 10 days after the treatment switch. The dose level of the 1-day formulation was kept unchanged for the first 2 days after the treatment switch.
  
  
  RESULTS
  The pain control rate with the 1-day formulation was 81.8% (54/66 patients). In 57.6% (38/66) of patients, the treatment switch to a low-dose 1-day formulation (0.3 or 0.6 mg x day(-1)) yielded sustained pain control. The adverse reactions to the 1-day formulation observed in this study were similar to those previously reported for the Durotep MT Patch (the "3-day formulation"). No severe adverse reactions, such as respiratory depression, were noted in the present study. Thus, the 1-day formulation was well-tolerated.
  
  
  CONCLUSIONS
  In patients with moderate to severe cancer pain, switching of opioid analgesic therapy to 1-day formulation therapy has been shown to be safe and useful, following rotation from other opioids, for controlling cancer pain. The demonstrated utility was similar to that associated with the 3-day formulation.
authors.affiliation: Department of Anesthesiology and Pain Relief Center, JR Tokyo General Hospital, Tokyo 151-8528.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hanaoka
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Tomoyasu
authors.initials: T
authors.lastname: Tomioka
authors.forename: Hideo
authors.initials: H
authors.lastname: Sakata
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D004304:Dosage Forms; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D004304:Dosage Forms; D005283:Fentanyl